11th World Congress on BIOSIMILARS AND BIOLOGICS

May 20-21, 2019 | Miami, USA

Posters & Accepted Abstracts

J Pharm Sci Emerg Drugs
Bio-Equivalence of Ciprofloxacin 500mg

Khalid Aftab and Sidrah Khan

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Biomimetic HPLC property measurements to estimate human in vivo distribution and tissue binding of drug discovery compounds

Valko KL

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Biosimilar assays: Guiding principles (PK, ADA and Nab) for a Bioanalytical scientist for a one or two assay choice

Aparna Kasinath

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Biosimilars: challenges in safety and risk management

Asif Mahmood

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Challenges for biosimilar drug development , scale up & higher scale manufacturing : Developed and developing country landscape.

Sumant Chaubey

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Challenges in quality control of biosimilars in India: Role of National Institute of Biologicals

Subhash Chand, J P Prasad, Surinder Singh

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Coronary flow regulation by adenosine it’s signaling

S Jamal Mustafa

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Development of a male contraceptive from traditionally used Indian medicinal plants

Pratap Chand Mali

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Direct evidence of viral infection and mitochondrial alterations in the brain of fetuses at high risk for schizophrenia

Segundo Mesa Castillo

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Food and nutrition security and its association with women and children health of deprived community

Ramu

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Growth potential of biosimilars in emerging countries

Md Abu Zafor Sadek

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Harnessing the power of the network to deliver biosimilar medicine trials

Divya Chadha Manek

PDF  |   HTML   
J Pharm Sci Emerg Drugs
How to address immunogenicity in the development of a rare disease biosimilar

Candida Fratazzi

PDF  |   HTML   
J Pharm Sci Emerg Drugs
How to increase Biosimilar access and commercialization success

James Harris

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Liquid –liquid extraction method developed for thymoquinone from seed powder of Nigella Sativa, characterized it by UV-spectrophotometer

Mohamad Taleuzzaman, Sadaf Jamal Gilani and Sayed Sarim Imam

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Navigating the Legal And Ip Challenges To Biosimilar Market Entry

Joanna T Brougher

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Newly approved antimicrobial agents: where do they belong?

Jonathan Cho

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Optimizing Clinical trials as part of the totality of data to support the marketing approval of biosimilars

Cecil J Nick

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in nili/ravi buffalos

Zahid Iqbal and Ijaz Javed

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Prevalence of intestinal parasitic infections and their associations with anthropometric measurements of school children in selected primary schools, Wukro Town, Eastern Tigray, Ethiopia

Eleni Kidane

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Thaumatin protein from African Thaumatococcus danielli in formulated organic drink and snack significantly improved the nutritional status in wistar rats

Oyebamiji Emmanuel Aanuoluwapo

PDF  |   HTML   
J Pharm Sci Emerg Drugs
The regulatory framework for similar biotherapeutic products in Cuba

Y Hechavarria Nunez, R Perez Massipe, L Martinez Munoz, D Orta Hernandez and V Perez Rodriguez

PDF  |   HTML   
J Pharm Sci Emerg Drugs
The US-FDA interchangeability guidance for biosimilars

Michel Mikhail

PDF  |   HTML   
J Pharm Sci Emerg Drugs
Treatment of metastatic or high-risk solid cancer patients by targeting immune system and/or tumor burden: Six cases report

Andrea Nicolini, Paola Ferrari and Angelo Carpi

PDF  |   HTML   

Track Your Manuscript

Media Partners

GET THE APP